One in eight or about 13% of American adults have used a GLP-1 agonist, a class of drugs prescribed for weight loss, to treat diabetes, or to reduce the risk of heart attack and stroke in adults with heart disease, a new survey found.
Half of those people or about 6% report they are currently taking one of these drugs, which includes Novo Nordisk’s Ozempic and Wegovy, and Eli Lilly’s Mounjaro and Zepbound, among others.
